The Professional Association for Transgender Health
Aotearoa (PATHA) is deeply concerned at further delays to
the publication of updated Guidelines for Gender Affirming
Healthcare in Aotearoa New Zealand.
PATHA
has been informed by Te Whatu Ora | Health New Zealand that
the updated Guidelines will not be published until the
Minister of Health decides on whether to introduce
regulations on the ability of medical professionals to
prescribe puberty blockers as part of gender affirming
healthcare.
The guideline’s advice on
prescribing puberty blockers was updated in November 2024 to
reflect the Ministry of Health’s position statement on the
use of these medications. This advice spans just 6 of the
total 182 pages of information contained in the guidelines.
The guidance is evidence-based, aligns with international
best practice and guidelines, and supports a holistic
approach to gender affirming medical care for young people
who need it.
“Medical professionals working in this
area are constantly being asked by colleagues for clinical
guidance on gender-affirming healthcare,” says Dr Rona
Carroll, a Specialist General Practitioner and
Vice-President of PATHA. “By not publishing the updated
guidelines, the government is stopping healthcare providers
from being guided by evidence-based, up-to-date New Zealand
specific information. We have been given no timeframe for
when to expect a decision about the puberty blocker
consultation or the updated guidelines. Considering how many
other areas of health these guidelines include, and that the
advice on prescribing puberty blockers is in line with the
Ministry’s position statement, the updated guidelines
should be published immediately. I think clinicians would be
providing safer care if they had access to these guidelines
today.”
Advertisement – scroll to continue reading
On Wednesday, 28 May, PATHA published an
open letter calling on the Minister of Health, Simeon Brown
and the Associate Minister for Health, Matt Doocey, to
release the updated guidance.
This letter was signed
by over 500 medical bodies, clinicians and community
organisations. Signatories include the Royal New Zealand
College of General Practitioners, the New Zealand Society of
Endocrinology, the College of Child and Youth Nurses, and
the Paediatric Society of New Zealand.
The
evidence-based guidelines, which have been peer reviewed by
clinicians with expertise in this care from within New
Zealand and internationally, provide detailed information on
a wide range of topics relevant to healthcare for
transgender and non-binary people. This includes several
revised chapters from the 2018 edition in line with emerging
medical research.
“I’m proud of the amount of work
the authors have put into these guidelines, bringing their
extensive collective expertise into creating guidance that
is broad and has a holistic view of transgender health,”
says Jennifer Shields, PATHA President. “These guidelines
cover so much more than puberty blocker medication, and this
information is important for all healthcare workers to
have.”
“It is clear that there is no
evidence-based justification for considering restrictions on
prescribing puberty blockers to transgender young people,”
Shields says. “These medications continue to be prescribed
to children for other indications, and limitations in the
quality of the academic evidence are not unique to this
care. Healthcare professionals are now left wondering if
this government is being pulled into alarming ‘culture
war’ trends away from best practice medical care, and into
anti-transgender policies that lead to a reduction in
patients’ rights and freedoms, and set precedent for making
clinical decisions based on political beliefs rather than
what’s best for patients.”
“This is clear
evidence of ideological interference in an operational,
professional frontline medical resource that is being
requested by the health sector,” Carroll said. “We
reiterate our call for the Government to allow Te Whatu Ora
Health New Zealand to publish these updated guidelines
immediately.”
Background
information
Statement on puberty
blockers
On 21st November 2024, the Ministry
of Health published a position statement on the use of
puberty blockers in gender affirming care, emphasising that
puberty blockers could continue to be prescribed when needed
as part of interdisciplinary teams. The Government expressed
an intention to explore further restrictions on access to
this care, and opened public consultation on possible
restrictions. This consultation closed on 20th January
2025.
A memo sent to then Minister of Health Shane
Reti on 30 April 2024 was released to PATHA under the
Official Information Act. In this memo, the Ministry of
Health clarified that:
“There is currently no
evidence that individual clinicians are prescribing [puberty
blockers] outside of an interprofessional
team.”
This shows that concerns about
individual professionals prescribing puberty blockers
inappropriately are unfounded, and current prescribing
practices are already in line with the Ministry’s position
statement.
PATHA previously published a collective
statement opposing the restrictions the Government is
considering on the prescription of puberty blockers to
transgender young people. This statement also received broad
support from medical bodies, including the New Zealand
Paediatrics Society and the New Zealand Society of
Endocrinology. The statement reads [in part]:
“The
Ministry of Health Evidence Brief identified that any
evidence of harm associated with providing puberty-blocking
medication is limited and inconclusive, and withholding this
care may exacerbate gender dysphoria and negatively impact
mental health. Equitable and non-discriminatory access to
this care should be provided and maintained throughout the
country.
Decisions about prescribing puberty blockers
should continue to be made collaboratively between young
people, their families or support people, and the health
professionals involved in their care. These decisions are
individualised, based on informed consent, and guided by
professional training, clinical experience, and the best
available evidence. Any move to restrict access to puberty
blockers would be a political decision and not one based on
clinical guidance from health experts in New Zealand and
international best practice. Medical decisions should remain
free from political
interference.”
Background on puberty
blockers
Puberty blockers are a medication
called gonadotrophic releasing hormone (GnRH) agonists. They
were developed in the 1980s for use in much younger children
with precocious (early) puberty, and have been used in
gender affirming care for over 20 years. They halt the
development of secondary sexual characteristics, such as
breast growth or voice deepening, and can relieve distress
associated with these bodily changes for transgender young
people. Puberty blockers have the benefit of allowing the
young person time before making any decisions regarding
starting on gender affirming hormone therapy.
The
effect puberty blockers have on pausing pubertal changes is
reversible. Once the puberty blocker medication has been
stopped, puberty will resume as it would have done without
medication.
All medications have known or potential
risks, but evidence and experience to date does not raise
significant concerns about the safety of puberty blockers.
As is the case in all medical prescribing, risks, side
effects and benefits of medications are discussed with
patients as part of the informed consent process before
prescribing.
There are also risks to not prescribing
medications when they are indicated. Puberty results in
irreversible physical changes, which can result in lifelong
distress and gender dysphoria for some transgender
people.
In every area of healthcare, decisions about
treatment and medication prescribing take all of these
aspects into account, and health professionals support
patients and their families to weigh up the pros and cons
for their individual situation. Gender affirming healthcare
is no different. Decisions about whether to start puberty
blockers are made between health professionals, young people
and their whānau. These are healthcare decisions which
should remain free from ideological political
interference.
Clinicians who initiate puberty blockers
should be experienced in providing gender affirming
healthcare and working within an interdisciplinary team. It
is essential that access to this care and to puberty blocker
medication is maintained.
Topics covered by
the updated Guidelines
Advice on the
prescription of puberty blockers is a small portion of the
content covered by the updated guidelines. The updated
guidance also includes detailed information on a broad
number of other areas of transgender health, including
whānau support, creating inclusive clinical environments,
non-medical and non-surgical gender affirmation, speech and
language therapy, fertility and sexual health, mental
wellbeing, gender-affirming hormone therapy, and
detransition, as well as specific guidance for Māori,
Pasifika, and refugee and asylum seeker trans
people.
© Scoop Media



















Discussion about this post